Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Pharmacodynamic activity of the lantibiotic MU1140.

Ghobrial OG, Derendorf H, Hillman JD.

Int J Antimicrob Agents. 2009 Jan;33(1):70-4. doi: 10.1016/j.ijantimicag.2008.07.028.

3.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10.

6.
7.

Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140.

Ghobrial O, Derendorf H, Hillman JD.

Eur J Pharm Sci. 2010 Dec 23;41(5):658-64. doi: 10.1016/j.ejps.2010.09.005.

PMID:
20869439
8.

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T Jr, Moeck G.

J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126.

PMID:
19369269
10.
11.

Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens.

Severina E, Severin A, Tomasz A.

J Antimicrob Chemother. 1998 Mar;41(3):341-7.

PMID:
9578160
12.

Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).

Zhao C, Sun H, Wang H, Liu Y, Hu B, Yu Y, Sun Z, Chu Y, Cao B, Liao K, Lei J, Hu Z, Zhang L, Zhang X, Xu Y, Wang Z, Chen M.

Diagn Microbiol Infect Dis. 2012 Jun;73(2):174-81. doi: 10.1016/j.diagmicrobio.2012.03.003.

PMID:
22521693
14.

Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.

Karlowsky JA, Nichol K, Zhanel GG.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S58-68. doi: 10.1093/cid/civ534.

PMID:
26316559
15.

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.

Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07.

16.

Cleistochlamys kirkii chemical constituents: Antibacterial activity and synergistic effects against resistant Staphylococcus aureus strains.

Pereira F, Madureira AM, Sancha S, Mulhovo S, Luo X, Duarte A, Ferreira MJ.

J Ethnopharmacol. 2016 Feb 3;178:180-7. doi: 10.1016/j.jep.2015.12.009.

PMID:
26674158
17.

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.

Jansen WT, Verel A, Verhoef J, Milatovic D.

Antimicrob Agents Chemother. 2007 Sep;51(9):3420-4.

18.

[Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].

Garnacho-Montero J, Amaya-Villar R, Gómez-Grande ML, Jerez V, Lorente-Ramos L, Loza A, Martínez A, Pozo JC, Sierra R, Pomares J, de la Torre MV, Ortiz C.

Rev Esp Quimioter. 2011 Mar;24(1):13-24. Review. Spanish.

19.

In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.

Cafini F, Aguilar L, González N, Giménez MJ, Torrico M, Alou L, Sevillano D, Vallejo P, Prieto J.

J Antimicrob Chemother. 2007 Jun;59(6):1185-9.

PMID:
17412725
20.

Supplemental Content

Support Center